Welcome to our dedicated page for MetLife SEC filings (Ticker: MET), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MetLife’s balance sheet stewards more than half a trillion dollars in insurance reserves and invested assets—numbers that translate into multi-layered disclosures spanning hundreds of pages. Finding where management explains reserve adequacy or how separate-account assets back variable annuity guarantees can feel daunting.
Stock Titan solves that problem. Our AI engine converts each MetLife annual report 10-K into an easy synopsis, highlights key shifts in credit‐quality of the investment portfolio, and flags loss-ratio trends inside every MetLife quarterly earnings report 10-Q filing. Need rapid context on a dividend declaration or reinsurance treaty? The moment a MetLife 8-K material events filing arrives in EDGAR, we post it with an “8-K material events explained” note. Real-time alerts also cover
- MetLife Form 4 insider transactions real-time
- MetLife proxy statement executive compensation
- MetLife executive stock transactions Form 4
Whether you’re comparing segment profit drivers or monitoring statutory capital, our platform keeps every document at your fingertips: MetLife insider trading Form 4 transactions, MetLife annual report 10-K simplified, MetLife SEC filings explained simply, and MetLife earnings report filing analysis. Stop combing through actuarial footnotes; understanding MetLife SEC documents with AI means you save hours and surface insights faster than ever.
MetLife, Inc. (MET) – Form 144 filing: The notice discloses a proposed sale of 101 common shares with an aggregate market value of $7,933.55. The shares were originally purchased on 12/17/2019 for cash and are slated to be sold through Barclays Capital on or about 06/20/2025 on the NYSE. The issuer has 671,297,826 shares outstanding, so the planned transaction represents less than 0.00002 % of equity. The filing also lists earlier sales by related MetLife accounts over the past three months totaling 686 shares for gross proceeds of $55,391.75. The signer affirms no undisclosed material adverse information and Rule 144 compliance.
MetLife Director Robert Glenn Hubbard acquired 964 shares of common stock on June 17, 2025, at a price of $77.85 per share, bringing his total direct beneficial ownership to 100,489 shares.
The acquisition was part of MetLife's non-management director compensation arrangements, where a portion of director retainer fees is paid in company common stock. Hubbard elected to defer the receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors.
Key transaction details:
- Transaction type: Acquisition of non-derivative securities
- Total value of transaction: Approximately $75,047 (964 shares × $77.85)
- Ownership form: Direct
- Filing made as an individual reporting person
MetLife Director Jeh C. Johnson reported the acquisition of 562 shares of common stock at $77.85 per share on June 17, 2025, bringing total direct ownership to 6,789 shares.
The transaction was part of MetLife's non-management director compensation arrangement, where a portion of director retainer fees is paid in company stock. Johnson elected to defer the receipt of these shares through the MetLife Deferred Compensation Plan for Non-Management Directors.
- Transaction Type: Acquisition (Code A)
- Form Type: Form 4 (Statement of Changes in Beneficial Ownership)
- Transaction Value: Approximately $43,752
- Ownership: Direct
This routine compensation-related transaction demonstrates continued alignment between director and shareholder interests through equity-based compensation.
MetLife director Denise M. Morrison reported the acquisition of 562 shares of common stock on June 17, 2025 as part of the company's non-management director compensation arrangements. The shares were acquired at $0 cost as part of director retainer fees paid in company stock.
Following this transaction, Morrison now beneficially owns a total of 32,817 shares directly. The filing indicates this is a routine compensation-related acquisition for board service rather than an open market purchase.
- Transaction Type: Stock Award (Compensation)
- Form of Ownership: Direct
- Role: Non-Management Director
- No derivative securities were involved in this transaction
MetLife director Christian Stephane Mumenthaler acquired 562 shares of common stock on June 17, 2025 at a price of $77.85 per share, bringing total direct ownership to 918 shares.
The transaction was part of MetLife's non-management director compensation arrangement, where a portion of director retainer fees is paid in company stock. Notably, Mumenthaler elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors.
- Transaction Type: Acquisition (Form 4)
- Total Transaction Value: $43,751.70
- Ownership Type: Direct
- Role: Non-Management Director
Form 4 overview – MetLife, Inc. (MET)
Director Mark A. Weinberger reported a routine equity award on 17 Jun 2025. He received 562 shares of MetLife common stock at a stated price of $0, reflecting the company’s practice of paying a portion of non-management director retainers in shares. Following the transaction, Weinberger’s direct ownership increased to 16,907 shares.
No derivative securities were involved and the filing contains no additional purchases, sales or option exercises. The award appears to be automatic, formula-based compensation and does not signal discretionary buying or selling by the director.
MetLife, Inc. (NYSE: MET) – Form 4 insider transaction filed 20 Jun 2025
Non-management director Diana McKenzie reported the acquisition of 562 shares of MetLife common stock on 17 Jun 2025 at a reference price of $77.85 per share. The transaction was coded “A(1),” indicating the shares were issued as part of the company’s non-management director compensation plan rather than an open-market purchase. After the grant, McKenzie’s direct beneficial ownership rose to 22,065 shares.
The filing notes that the director elected to defer receipt of the shares under the MetLife Deferred Compensation Plan for Non-Management Directors. No derivative securities were reported, and there were no dispositions.
While the amount is immaterial relative to MetLife’s ~805 million shares outstanding, routine equity compensation aligns director incentives with shareholder returns and remains a data point for governance and insider-sentiment trackers.
MetLife, Inc. (MET) – Form 4 insider transaction filed 20 June 2025
Independent director William E. Kennard reported an automatic acquisition of 562 common shares on 17 June 2025. The shares were credited at a reference price of $77.85 under the company’s non-management director compensation program and immediately deferred into the MetLife Deferred Compensation Plan for Non-Management Directors. No open-market cash outlay occurred.
Following the transaction, Kennard’s direct ownership stands at 43,606 common shares. He also retains 10 shares indirectly through the MetLife Policyholder Trust, bringing his total reported beneficial holding to 43,616 shares.
The filing carries code “A(1),” indicating an exempt award related to board fees rather than discretionary buying or selling. No derivative securities were involved, and there were no dispositions. The update is routine, modest in size (<0.001 % of shares outstanding), and does not affect MetLife’s capital structure or liquidity.
Key takeaways for investors
- Incremental increase in insider equity aligns director incentives with shareholders.
- Because the shares were part of standard board compensation, the filing does not signal strategic sentiment or anticipated operational developments.
- Beneficial ownership data remains well below any control threshold; governance dynamics unchanged.
MetLife, Inc. (MET) filed a Form 4 reporting routine insider activity by non-management director Carlos M. Gutierrez. On 06/17/2025, Gutierrez received 562 shares of common stock (transaction code A) at a stated price of $0, reflecting the company’s policy to pay a portion of director retainers in equity. Following the grant, the director now owns 23,851 shares directly and 18,807 shares indirectly through the Carlos M. Gutierrez Trust. No derivative securities were involved, and the filing contains no sales or dispositions.
MetLife, Inc. (MET) – Form 4 insider transaction
Director Carla A. Harris disclosed the acquisition of 562 MetLife common shares on 17 Jun 2025. The reference price reported was $77.85, implying a transaction value of roughly $43.7 thousand. The shares stem from the company’s normal non-management director compensation program and were deferred through the MetLife Deferred Compensation Plan for Non-Management Directors. Post-transaction ownership equals 8,484 directly held shares. No derivative positions were created or exercised, and no shares were sold. The filing appears routine and compensation-related, with limited impact on overall share float or corporate governance.